KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Equity (2016 - 2025)

Historic Return on Equity for Halozyme Therapeutics (HALO) over the last 15 years, with Q3 2025 value amounting to 1.42%.

  • Halozyme Therapeutics' Return on Equity rose 3700.0% to 1.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.42%, marking a year-over-year increase of 3700.0%. This contributed to the annual value of 1.98% for FY2024, which is 2400.0% down from last year.
  • As of Q3 2025, Halozyme Therapeutics' Return on Equity stood at 1.42%, which was up 3700.0% from 1.37% recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Return on Equity ranged from a high of 2.44% in Q2 2021 and a low of 1.06% during Q3 2024
  • For the 5-year period, Halozyme Therapeutics' Return on Equity averaged around 1.58%, with its median value being 1.49% (2021).
  • Its Return on Equity has fluctuated over the past 5 years, first skyrocketed by 29300bps in 2021, then crashed by -12900bps in 2025.
  • Halozyme Therapeutics' Return on Equity (Quarter) stood at 1.68% in 2021, then dropped by -10bps to 1.52% in 2022, then grew by 12bps to 1.69% in 2023, then crashed by -36bps to 1.09% in 2024, then surged by 31bps to 1.42% in 2025.
  • Its last three reported values are 1.42% in Q3 2025, 1.37% for Q2 2025, and 1.15% during Q1 2025.